Since patients with BrM and LMD do not routinely undergo CNS biopsy, we developed a novel LAT1 staining protocol and grading scale used post hoc, to test any available patient sample and correlate with treatment response, we developed a novel LAT1 staining protocol and grading scale. Here, SLC7A5 is linked to Langer mesomelic dysplasia.